Monash IVF's Rejected Takeover Bid Gives Way to a Management Reset

Embryo transfer mistakes triggered a sharp sell-off, an underpriced private equity bid was rejected, and new management is now delivering a genuine operational turnaround.

2 Sep 2026 · 3 min read

Monash IVF Group's embryo transfer mistakes triggered a media-accelerated share price collapse of more than 30 percent, before an opportunistic private equity takeover approach at $0.80 a share, priced well below comparable fertility sector transactions, was rejected by the board, and a new management team's operational reset has since left fund managers arguing the stock offers a more robust opportunity.

Embryo transfer mistakes trigger a media-driven collapse

Asymmetric Asset Management said the fund's outperformance was driven partly by Monash IVF, which received a takeover approach from joint bidding partners Washington H Soul Pattinson and private equity firm Quantum, having been a buyer of the shares earlier in the year after a series of negative announcements led to a more than 30 percent drop, even as news headlines made for unpleasant reading. Seneca Financial Solutions said the stock rallied 23 percent after receiving an opportunistic takeover bid from private equity group Genesis Capital at $0.80 a share, noting Monash IVF had disappointed over the prior couple of years after embryo transfer mistakes saw the company caught up in a media-accelerated sell-off, with Seneca adding to its position after the share price weakness given the company maintains a very strong market position.

MVF has disappointed over the last couple of years, after a couple of embryo transfer mistakes saw the company get caught up in a media-accelerated sell-off. However, we added to the position after this share price weakness, given that the company maintains a very strong market position.

— Seneca Financial Solutions, Monthly Report, November 2025

An opportunistic bid rejected as underpriced

Seneca Financial Solutions said it views the takeover bid received, from a Genesis Capital and Soul Patts consortium at $0.80 a share, implying around 8 times earnings, as opportunistic, given comparable fertility-sector transactions have priced at 12 to 14 times earnings, with the board declining to support the offer at that level, leaving Seneca to see the stock as cheap and now genuinely in play for a revised approach.

Seneca views the takeover bid received (from a Genesis Capital/Soul Patts consortium at $0.80/share, implying ~8x earnings) as opportunistic, given comparable fertility-sector transactions have priced at 12-14x. The board did not support the offer at that level.

— Seneca Financial Solutions, Article, January 2026

A new management team resets the business

Yarra Capital Management said Monash IVF has a new management team putting its stamp on the business as it comes to the end of a capex cycle, with prior corporate interest in the stock and a move toward a more regulated, scale-favouring market, better second-half trends, continued share gains, and better clinical outcomes seen as making it a more robust opportunity at current value, describing a basing effect following past corporate interest.

Liked new management stamping its mark as the business exits a capex cycle, with better second-half trends, market-share gains and improved clinical outcomes. Sees a 'basing' effect following past corporate interest and a shift toward a more regulated, scale-favouring market.

— Yarra Capital Management, Presentation, August 2026

What fund managers say they are watching next is whether a revised takeover approach emerges given the board's rejection of the underpriced Genesis Capital and Soul Patts bid, continued improvement in clinical outcomes and market share gains under new management, delivery of benefits as the business exits its capex cycle, and whether regulatory changes favouring scale continue benefiting Monash IVF's market position.